6-O-benzylguanine
- Generic Name
- 6-O-benzylguanine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11N5O
- CAS Number
- 19916-73-5
- Unique Ingredient Identifier
- 01KC87F8FE
- Background
6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00002604
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Cleveland, Cleveland, Ohio, United States
🇺🇸Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00086970
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004892
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005081
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00003765
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 12
- Registration Number
- NCT00005066
- Locations
- 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
- Conditions
- Interventions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT00003766
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Duke University
- Registration Number
- NCT00046878
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
- Conditions
- Locations
- 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
- Conditions
- Childhood EpendymoblastomaChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial Ependymoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00052780
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.